Table 3.
Comparison of Response to Teneligliptin Switching
| Non-Responder (N=120) | Responder (N=44) | P value | |
|---|---|---|---|
| Age, years | 74.4 ± 6.1 | 74.9 ± 6.6 | 0.627 |
| Male sex, N (%) | 46 (38.3) | 23 (52.3) | 0.109 |
| Duration of type 2 diabetes, years | 15.3 ± 13.7 | 18.0 ± 11.1 | 0.245 |
| Body mass index, kg/m2 | 25.3 ± 3.6 | 25.0 ± 3.1 | 0.661 |
| Fasting blood glucose, mg/dl, baseline | 142.9 ± 41.0 | 160.8 ± 57.5 | 0.064 |
| Fasting blood glucose, mg/dl, after switching | 141.2 ± 37.9 | 135.0 ± 56.0** | 0.428 |
| HbA1c, %, baseline | 7.6 ± 1.1 | 8.9 ± 1.4 | <0.001 |
| HbA1c, %, after switching | 7.6 ± 1.3 | 7.3 ± 1.0** | 0.118 |
| Postprandial blood glucose, mg/dl, baseline | 220.3 ± 76.2 | 240.3 ± 82.2 | 0.163 |
| Postprandial blood glucose, mg/dl, after switching | 199.2 ± 68.0** | 222.8 ± 74.7 | 0.089 |
| eGFR, mL/min/1.73m2, baseline | 64.7 ± 24.5 | 59.4 ± 29.1 | 0.173 |
| eGFR, mL/min/1.73m2, after switching | 60.1 ± 22.2 | 54.4 ± 28.8 | 0.242 |
| Total cholesterol, mg/dl, baseline* | 161.2 ± 39.0 | 145.5 ± 30.5 | 0.122 |
| Total cholesterol, mg/dl, after switching* | 152.8 ± 37.0** | 152.6 ± 48.9 | 0.696 |
| Triglyceride, mg/dl, baseline* | 159.0 ± 75.3 | 120.8 ± 61.5 | 0.007 |
| Triglyceride, mg/dl, after switching* | 154.7 ± 74.0 | 126.7 ± 53.3 | 0.017 |
| HDL cholesterol, mg/dl, baseline* | 43.0 ± 10.9 | 45.6 ± 17.1 | 0.789 |
| HDL cholesterol, mg/dl, after switching* | 42.7 ± 10.0 | 46.3 ± 20.1 | 0.672 |
| LDL cholesterol, mg/dl, baseline* | 87.4 ± 32.6 | 80.6 ± 23.1 | 0.740 |
| LDL cholesterol, mg/dl, after switching* | 78.4 ± 31.3** | 80.4 ± 36.5 | 0.914 |
| Medications, N (%) | |||
| Metformin | 77 (64.2) | 22 (50.0) | 0.100 |
| SU | 54 (45.0) | 25 (56.8) | 0.180 |
| TZD | 6 (5.0) | 4 (9.1) | 0.332 |
| Insulin | 30 (25.0) | 18 (40.9) | 0.047 |
| Statin | 85 (70.8) | 25 (56.8) | 0.091 |
Notes: Data are presented as N (%) or mean ± SD. *Log transformed. **P<0.05 compared with baseline.
Abbreviations: HbA1c, glycated hemoglobin A1c; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; HDL cholesterol, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; AST, aspartate transaminase; ALT, alanine transferase; SU, sulfonylurea; TZD, thiazolidinedione; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.